Effect of Clostridium butyricum on fecal flora in Helicobacter pylori eradication therapy.
OBJECTIVE
To investigate the effect of probiotic bacterium, Clostridium butyricum MIYAIRI 588 strain (CBM) on the changes of the fecal flora in Helicobacter pylori (H. pylori) treatment.


METHODS
Thirty-five patients with gastric or duodenal ulcers positive for H. pylori were randomized either to 1 wk amoxicillin, clarithromycin, lansoprazole (Group 1) or to the same regimen supplemented with CBM 7 d ahead of the triple therapy (Group 2). Stool samples were collected before and 2, 4, 7, 15, and 22 d after the starting eradication therapy, and were examined intestinal flora. Patients were required to keep a diary record of their condition.


RESULTS
Obligate anaerobes decreased significantly on d 2, 4, 8 and 15 in Group 1. On the other hand, they did not decrease significantly in Group 2. The Escherichia coli was dominant bacterium in Enterobacteriaceae, but that was replaced by other species such as Klebsiella and Enterobacter after eradication in Group 1. The change was suppressed in Group 2. Abdominal symptoms were less frequent in Group 2 than in Group 1.


CONCLUSIONS
The combined use of CBM reduced the changes in the intestinal flora and decreased the incidence of gastrointestinal side effects.
Shimbo
Izumi
I
Department of Medicine and Clinical Oncology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba-City, Chiba, 260-0856, Japan.
Yamaguchi
Taketo
T
Odaka
Takeo
T
Nakajima
Kenichi
K
Koide
Akinori
A
Koyama
Hidehiko
H
Saisho
Hiromitsu
H
D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D046972:Clostridium butyricum; D003131:Combined Modality Therapy; D005243:Feces / Q000382:microbiology; D005260:Female; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori; D006801:Humans; D008297:Male; D008875:Middle Aged; D019936:Probiotics / Q000008:administration & dosage*
D000900:Anti-Bacterial Agents